Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 374

1.

The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.

Lapham S, Forman R, Alexander M, Illeperuma A, Bohn MJ.

J Subst Abuse Treat. 2009 Jan;36(1):1-6. doi: 10.1016/j.jsat.2008.07.001. Epub 2008 Sep 4.

PMID:
18775624
2.

Early treatment response in alcohol dependence with extended-release naltrexone.

Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM.

J Clin Psychiatry. 2008 Feb;69(2):190-5.

PMID:
18348601
3.

Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.

Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR.

Alcohol Clin Exp Res. 2011 Oct;35(10):1804-11. doi: 10.1111/j.1530-0277.2011.01524.x. Epub 2011 May 16.

PMID:
21575016
4.

Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR.

J Clin Psychopharmacol. 2007 Oct;27(5):507-12.

PMID:
17873686
5.

Extended-release naltrexone for treatment of alcohol dependence in primary care.

Lee JD, Grossman E, DiRocco D, Truncali A, Hanley K, Stevens D, Rotrosen J, Gourevitch MN.

J Subst Abuse Treat. 2010 Jul;39(1):14-21. doi: 10.1016/j.jsat.2010.03.005. Epub 2010 Apr 2.

PMID:
20363090
6.
7.

Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.

Lee JD, Grossman E, Huben L, Manseau M, McNeely J, Rotrosen J, Stevens D, Gourevitch MN.

J Subst Abuse Treat. 2012 Dec;43(4):458-62. doi: 10.1016/j.jsat.2012.08.012. Epub 2012 Sep 15.

PMID:
22985676
8.

Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS.

Alcohol Clin Exp Res. 2009 Feb;33(2):350-6. doi: 10.1111/j.1530-0277.2008.00843.x. Epub 2008 Nov 25.

9.

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.

Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, Mäkelä R.

Alcohol Clin Exp Res. 2007 Jul;31(7):1179-87. Epub 2007 Apr 19.

PMID:
17451401
10.

Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.

Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK.

Alcohol Clin Exp Res. 2001 Nov;25(11):1634-47.

PMID:
11707638
11.

Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.

Lapham SC, McMillan GP.

J Addict Med. 2011 Sep;5(3):163-9. doi: 10.1097/ADM.0b013e3181eb3b89.

PMID:
21844831
12.

Effectiveness of naltrexone in a community treatment program.

Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, Anton RF.

Alcohol Clin Exp Res. 2004 Nov;28(11):1710-7.

PMID:
15547458
13.

Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study.

Caputo F, Addolorato G, Lorenzini F, Domenicali M, Greco G, del RE A, Gasbarrini G, Stefanini GF, Bernardi M.

Drug Alcohol Depend. 2003 May 1;70(1):85-91.

PMID:
12681528
14.

Naltrexone improves outcome of a controlled drinking program.

Rubio G, Manzanares J, Lopez-Muñoz F, Alamo C, Ponce G, Jimenez-Arriero MA, Palomo T.

J Subst Abuse Treat. 2002 Dec;23(4):361-6.

PMID:
12495798
15.

The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.

Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA.

J Clin Psychopharmacol. 2006 Dec;26(6):610-25. Review.

PMID:
17110818
16.

Extended-release intramuscular naltrexone.

Swainston Harrison T, Plosker GL, Keam SJ.

Drugs. 2006;66(13):1741-51. Review.

PMID:
16978037
17.

Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.

Lucey MR, Silverman BL, Illeperuma A, O'Brien CP.

Alcohol Clin Exp Res. 2008 Mar;32(3):498-504. doi: 10.1111/j.1530-0277.2007.00593.x. Epub 2008 Jan 30.

PMID:
18241321
18.

Intramuscular extended-release naltrexone: current evidence.

Gastfriend DR.

Ann N Y Acad Sci. 2011 Jan;1216:144-66. doi: 10.1111/j.1749-6632.2010.05900.x. Review. Erratum in: Ann N Y Acad Sci. 2011 Apr;1224(1):207. Ann N Y Acad Sci. 2011 Apr;1224(1):207.

PMID:
21272018
19.

Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.

Finigan MW, Perkins T, Zold-Kilbourn P, Parks J, Stringer M.

J Subst Abuse Treat. 2011 Oct;41(3):288-93. doi: 10.1016/j.jsat.2011.04.003. Epub 2011 Jun 21.

PMID:
21696912
20.

Opioid antagonists for alcohol dependence.

Srisurapanont M, Jarusuraisin N.

Cochrane Database Syst Rev. 2000;(3):CD001867. Review. Update in: Cochrane Database Syst Rev. 2002;(2):CD001867.

PMID:
10908513

Supplemental Content

Support Center